Turning the Tide: How Public Health Policies are Winning Against HIV
"A new look at how robust strategies in New York City offer a blueprint for combating the HIV epidemic."
Public health policies designed to address the HIV epidemic are multifaceted, considering the diverse populations affected. Recent research highlights the effectiveness of robust public health strategies in driving down HIV rates. This article explores how these policies have succeeded and what lessons can be applied more broadly.
A study by Des Jarlais and colleagues [1] identifies key trends in the reduction of HIV prevalence among non-injection drug users (NIDU) in New York City. Their findings underscore the importance of comprehensive public health interventions that tackle multiple factors simultaneously, such as drug use, healthcare access, and HIV prevention.
Adaptable local prevention strategies have proven effective in decreasing HIV prevalence [2]. Data from Des Jarlais and colleagues [1] supports this. Further evidence from Okeke and colleagues [3] in San Francisco shows substantial improvements in care for African American men who have sex with men (MSM) between 2004 and 2014, coinciding with a decrease in HIV prevalence within this group. These successes highlight the importance of targeted, high-impact prevention strategies.
HIV in the United States
HIV.gov reports that approximately 1.2 million people in the United States have HIV, and about 13% of them do not know it and need testing. The page notes that HIV disproportionately affects some populations, particularly racial and ethnic minorities and gay and bisexual people. It also distinguishes HIV incidence—the estimated number of new infections during a period—from diagnoses made in that period.
Detection, Tailored Services, and Implementation
The Ending the HIV Epidemic strategy describes detecting HIV and then using local public health officials, community-based organizations, and other partners to address gaps in prevention and treatment services. Its stated aim is to stop ongoing transmission by ensuring tailored services reach the people and places that need them. A 2023 Lancet Seminar also focuses on clinical, implementation, and public health issues in the HIV prevention and treatment landscape.
Milestones in the HIV Response
HIV.gov’s timeline follows the history of HIV and AIDS in the United States from the first reported cases in 1981 to the present. The AIDS.gov 30-year timeline report describes a call for a “massive media, educational and public health campaign” to curb HIV spread, as well as for a National Commission on AIDS. KFF’s global timeline is an ongoing reference to political, scientific, cultural, and community developments in the epidemic.
The Power of Comprehensive Strategies
While community viral load (an aggregate measure of the viral load within a population) remains a topic of discussion [6,7], Des Jarlais and colleagues identify significant increases in ART utilization. These trends suggest that reducing infectiousness at the community level correlates with a decrease in HIV prevalence.
- Targeting high-impact populations.
- Providing community-focused testing and diagnosis.
- Offering immediate/same-day ART.
- Supporting drug detoxification programs.
Current Reviews and Guidance
The Lancet’s November 2023 Seminar reviews the current HIV prevention and treatment landscape, emphasizing clinical, implementation, and public health issues relevant to generalist and HIV providers. JAMA’s HIV collection highlights recent guidelines and advances in prevention, screening, diagnosis, and treatment. Together, these sources describe reviews and guidance spanning both service delivery and clinical practice.
Limits of Treatment-as-Prevention Trials
The ANRS TasP trial did not demonstrate a reduction in HIV incidence, according to its report. The source explains that the offer of universal testing and treatment in intervention communities did not increase antiretroviral therapy coverage or population viral suppression compared with standard care in control communities. It therefore describes a failure to demonstrate reduced incidence in that trial, rather than evidence from a comparison in which coverage and suppression increased.
U.S. Care and Viral Suppression Measures
The CDC reports that among more than 1.1 million people living with diagnosed HIV at year-end 2024, 77% had received some care, 56% were retained in care, and 69% had achieved viral suppression. Separately, CDC surveillance estimated that 65% of people with diagnosed HIV in 48 states and the District of Columbia were virally suppressed in 2022. These figures refer to different years and descriptions of the populations measured, so they should not be treated as a direct like-for-like comparison.
Looking Ahead: Sustaining Progress and Adapting Strategies
Although behavioral and biomedical research has not yet produced a single, unified strategy to eradicate the HIV epidemic, combining multiple strategies remains key to achieving further success. Measuring the effectiveness of prevention strategies remains a challenge, but the data presented by Des Jarlais and colleagues strongly suggests that infections have been averted.
Equity and Access as Policy Priorities
A Lancet article argues that unequal healthcare access perpetuates racial and ethnic HIV disparities and calls for health policy change to correct the course of the U.S. epidemic. The National HIV/AIDS Strategy 2023 Interim Action Report says the United States is making progress toward eliminating HIV transmission but must accelerate its efforts. It also identifies barriers to comprehensive prevention and treatment that limit awareness, access, and engagement among priority populations with or most at risk of HIV.
Integration, Leadership, and Investment
A 2026 review includes studies of HIV prevention functions, supporting health-system functions, and integration of HIV prevention into public health and community health systems. A global policy briefing says political leadership is important to keep HIV prevention a public health priority. It also emphasizes greater investment in prevention, particularly investment that drives research and development innovation.
A Proposed PrEP Demonstration Project
For Fiscal Year 2017, the President’s budget request proposed a small demonstration project related to PrEP. Under the proposal, state health departments would have been permitted to use a small part of their federal HIV prevention funding for PrEP medications. The source presents this as a budget proposal, not as a report of results from an implemented project.
Dismissing these findings as merely the result of natural attrition would be a mistake. The observed trends—increased ART utilization alongside decreased unsafe sex practices—indicate that prevention messages are reaching the intended audience and influencing behavior.
Future research should focus on integrating available data and tailoring policies to meet the specific needs of high-impact communities. Des Jarlais and colleagues' findings demonstrate the significant impact of changes in drug use and community viral load on HIV prevalence. The decline in HIV prevalence among NIDU entering treatment in New York City between 2005 and 2014 highlights the transformative potential of sustained, population-level public health initiatives.